Give immunotherapy in the morning
Several studies found patients infused with checkpoint inhibitors earlier in the day lived longer. If a randomised trial confirms it, it is a free improvement available everywhere tomorrow.
Retrospective cohorts (Lancet Oncology 2021, multiple follow-ups) and the small randomised MEMOIR signal associate morning infusions with better survival, plausibly via circadian T-cell trafficking.
Pages like this
not linked directly; found by shared links- IdeaMicrobiome transplant as a routine immunotherapy adjunct
Shares Gustave Roussy, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Melanoma and the tags mechanism, open-question.
- IdeaWhat actually holds T cells at the tumour border?
Shares Gustave Roussy, PD-1 / PD-L1 immune checkpoint & T-cell activation, Memorial Sloan Kettering Cancer Center, PD-1 and the tags mechanism, open-question.
- IdeaMap metabolic dependencies in the patient, not the dish
Shares Memorial Sloan Kettering Cancer Center, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Memorial Sloan Kettering Cancer Center, Melanoma and the tags mechanism, open-question.
- IdeaKill drug-tolerant persisters through ferroptosis
Shares Melanoma, Non-small-cell lung cancer and the tags mechanism, open-question.
- IdeaCut the nerve supply to tumours with old drugs
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaIs aneuploidy itself a druggable vulnerability?
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.
- IdeaWhat makes a neoantigen actually immunogenic?
Shares Memorial Sloan Kettering Cancer Center and the tags mechanism, open-question.